URL copied Image Source : AP
A health worker prepares to administer the COVAXIN vaccine for COVID-19 to a man at an indoor stadium. (Representational image)
Drugs Controller General of India (DGCI) has approved emergency use for Zydus Cadila s Pegylated Interferon alpha-2b, Virafin  for treating moderate COVID-19 infection in adults.
Earlier, Zydus Cadila announced that its Phase III clinical trials with Pegylated Interferon Alpha 2b, PegiHep has shown promising results in treating Covid-19.
In what could be a breakthrough in the disease management of Covid, the interim results indicate that PegIFN when administered early on, could help patients recover faster and avoid much of the complications seen in the advanced stages of the disease.